SEC charges former New York investment analyst with alleged healthcare insider trading

Traders Union
All News
Regulators News
SEC charges NY analyst insider trading

Highlights

The SEC charged former New York investment analyst Li on June 5, 2026, alleging insider trading in healthcare companies using confidential non-public information.
Li allegedly traded securities ahead of public releases about private placements and clinical trial results, violating Section 10(b) and Rule 10b-5 of the Securities Exchange Act of 1934.
Parallel civil and criminal actions, including those from the U.S. Attorney's Office, intensify regulatory scrutiny of investment professionals' handling of market-sensitive healthcare data.

Complaint details and alleged trading scheme

As reported by the Securities and Exchange Commission, the agency charged Li on June 5, 2026, alleging he misused material non-public information accessed through his role at a registered investment adviser focused on healthcare companies.

The SEC says Li obtained confidential information after his employer was wall-crossed on client matters including upcoming securities offerings, private placement terms and clinical drug trial results. Regulators allege he then traded in those companies' securities before the information became public and used the information for personal gain.

The civil complaint, filed in the U.S. District Court for the Southern District of New York, accuses Li of violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. The SEC is seeking a permanent injunction, disgorgement with prejudgment interest, civil penalties and a conduct-based injunction barring him from acting as or associating with an investment adviser.

Parallel criminal case and enforcement impact

Li is also charged on June 5, 2026, in a parallel criminal action brought by the U.S. Attorney's Office for the Southern District of New York. The case adds to scrutiny of how investment professionals handle confidential information tied to capital markets transactions and clinical data in the healthcare sector.

The SEC says the investigation was conducted by Kim Han, Janna Berke and Melissa Coppola under the supervision of Mark Sylvester in the agency's New York Regional Office. The litigation is being led by Christopher M. Colorado and Kim Han, with assistance from the U.S. Attorney's Office for the Southern District of New York, the FBI and the Financial Industry Regulatory Authority.

Our earlier update on the Federal Election Commission’s June 1–5, 2026 weekly agenda focused on a litigation-heavy docket and an inspector general review of internal controls and risk management. It highlighted new court filings across multiple cases in Washington and underscored how procedural legal actions and compliance oversight were driving the agency’s work that week.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.